UBS’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$14K Sell
1,500
-150
-9% -$1.53K ﹤0.01% 8504
2014
Q2
$19K Hold
1,650
﹤0.01% 8186
2014
Q1
$17K Sell
1,650
-2,544
-61% -$36.7K ﹤0.01% 8347
2013
Q4
$54K Buy
4,194
+1,872
+81% +$25.8K ﹤0.01% 6873
2013
Q3
$35K Sell
2,322
-9,588
-81% -$115K ﹤0.01% 7352
2013
Q2
$111K Buy
+11,910
New +$80.7K ﹤0.01% 5784

Other funds holding RPTP

UBS's RPTP Position: Q3 2014 in Review

UBS reduced its RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) stake by 9.1% in Q3 2014, selling an estimated $1.53K and leaving 1,500 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #8504.

UBS first reported a position in RPTP in Q2 2013 and has held it in 6 quarters since. The position peaked at $111K in Q2 2013. 82 funds tracked by Wall St. Rank hold RPTP as of Q3 2014.

  • UBS held 1,500 shares of RAPTOR PHARMACEUTICAL CORP COM STK (DE) worth $14K as of Q3 2014.
  • UBS sold 150 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2014, an estimated $1.53K.
  • RAPTOR PHARMACEUTICAL CORP COM STK (DE) made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8504 holding.
  • UBS first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and has held it in 6 quarters since.
  • UBS's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $111K in Q2 2013.
  • 82 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.